| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.7.6.905 |
| P698 | PubMed publication ID | 15992006 |
| P2093 | author name string | Phillips RM | |
| P2860 | cites work | Serial analysis of gene expression | Q27860777 |
| SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells | Q28303921 | ||
| Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line | Q28379069 | ||
| Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours | Q29618396 | ||
| Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145 | Q31015729 | ||
| Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma | Q33207264 | ||
| Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo | Q33332643 | ||
| Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma | Q33460526 | ||
| Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase | Q33630320 | ||
| SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours | Q35976983 | ||
| Bioreductive drugs and the selective induction of tumour hypoxia | Q35982455 | ||
| SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures | Q35983232 | ||
| Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine | Q36080580 | ||
| DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. | Q36080706 | ||
| Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma | Q36080931 | ||
| EO9: relationship between DT-diaphorase levels and response in vitro and in vivo | Q36081106 | ||
| Activity and immunohistochemistry of DT-diaphorase in hamster and human kidney tumours. | Q53470719 | ||
| Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. | Q53470764 | ||
| DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. | Q53497663 | ||
| Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. | Q54242445 | ||
| Effects of bioreductive agents, tirapazamine and mitomycin C, on quiescent cell populations in solid tumors, evaluated by micronucleus assay. | Q55260558 | ||
| Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation. | Q55291376 | ||
| Targeting gene expression to hypoxic tumor cells | Q57377984 | ||
| Measurement of Tumor Oxygenation: A Comparison between Polarographic Needle Electrodes and a Time-Resolved Luminescence-Based Optical Sensor | Q58313833 | ||
| Life (and death) in a malignant tumour | Q59098941 | ||
| Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C | Q36081554 | ||
| The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis | Q36081564 | ||
| Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity | Q36081569 | ||
| Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. | Q36081630 | ||
| Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy | Q36134960 | ||
| Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee | Q36135297 | ||
| Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study | Q36138687 | ||
| The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. | Q36294962 | ||
| Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase | Q36430899 | ||
| Use of power Doppler ultrasound-guided biopsies to locate regions of tumour hypoxia | Q36431380 | ||
| Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069 | Q36431422 | ||
| Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overview | Q39477090 | ||
| Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity | Q39636042 | ||
| Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours. | Q39713362 | ||
| The histological structure of some human lung cancers and the possible implications for radiotherapy | Q39979244 | ||
| The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours | Q39995096 | ||
| Tumour hypoxia: the picture has changed in the 1990s | Q40620931 | ||
| Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent | Q40848107 | ||
| Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). | Q40848113 | ||
| Cellular approaches to bioreductive drug mechanisms | Q40848119 | ||
| The experimental development of bioreductive drugs and their role in cancer therapy. | Q40848141 | ||
| Radicals from one-electron reduction of nitro compounds, aromatic N-oxides and quinones: the kinetic basis for hypoxia-selective, bioreductive drugs | Q41004256 | ||
| Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. | Q41045940 | ||
| 2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo | Q41099033 | ||
| Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity | Q41099312 | ||
| Detection of subpopulations resistant to DNA-damaging agents in spheroids and murine tumours | Q41114816 | ||
| The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action | Q41140226 | ||
| Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase | Q41145264 | ||
| Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines | Q41185056 | ||
| Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. | Q41218087 | ||
| Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase | Q41390065 | ||
| Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers | Q41528100 | ||
| Metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) by purified DT-diaphorase under aerobic and anaerobic conditions | Q41577869 | ||
| EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models | Q41579896 | ||
| Role of nitric oxide in angiogenesis and microcirculation in tumors | Q41739532 | ||
| AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo | Q41844441 | ||
| Differences in vascular response between primary and transplanted tumours | Q41963023 | ||
| Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection | Q42104084 | ||
| An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours | Q42133214 | ||
| DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? | Q42142796 | ||
| Activation of misonidazole by rat liver microsomes and purified NADPH-cytochrome c reductase | Q42258013 | ||
| Are cancer cells acidic? | Q42372356 | ||
| Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase | Q42590553 | ||
| Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo. | Q42860709 | ||
| Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo | Q43489651 | ||
| Isolation and structure of an intrastrand cross-link adduct of mitomycin C and DNA | Q43639756 | ||
| Reassignment of the guanine-binding mode of reduced mitomycin C. | Q44212368 | ||
| Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1 | Q45324919 | ||
| Sequence-selective alkylation and cross-linking induced by mitomycin C upon activation by DT-diaphorase | Q46200986 | ||
| Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors | Q48105624 | ||
| Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. | Q50506494 | ||
| Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine. | Q51631643 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 905-928 | |
| P577 | publication date | 1998-06-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Prospects for bioreductive drug development | |
| P478 | volume | 7 |
Search more.